AR126718A1 - Composiciones y métodos para la degradación selectiva de proteínas diseñadas por ingeniería - Google Patents
Composiciones y métodos para la degradación selectiva de proteínas diseñadas por ingenieríaInfo
- Publication number
- AR126718A1 AR126718A1 ARP220102109A ARP220102109A AR126718A1 AR 126718 A1 AR126718 A1 AR 126718A1 AR P220102109 A ARP220102109 A AR P220102109A AR P220102109 A ARP220102109 A AR P220102109A AR 126718 A1 AR126718 A1 AR 126718A1
- Authority
- AR
- Argentina
- Prior art keywords
- tautomers
- pharmaceutically acceptable
- acceptable salts
- degradation
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000008684 selective degradation Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 8
- 230000015556 catabolic process Effects 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 7
- 238000006731 degradation reaction Methods 0.000 abstract 7
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 4
- 239000004475 Arginine Chemical group 0.000 abstract 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 3
- 229960003121 arginine Drugs 0.000 abstract 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 229960000310 isoleucine Drugs 0.000 abstract 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 3
- 229930182817 methionine Chemical group 0.000 abstract 3
- 229960004452 methionine Drugs 0.000 abstract 3
- 239000004471 Glycine Chemical group 0.000 abstract 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 2
- 229960002743 glutamine Drugs 0.000 abstract 2
- 229960002449 glycine Drugs 0.000 abstract 2
- 229960002885 histidine Drugs 0.000 abstract 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Chemical group OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 2
- 229960003136 leucine Drugs 0.000 abstract 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 2
- 229960005190 phenylalanine Drugs 0.000 abstract 2
- 229960004799 tryptophan Drugs 0.000 abstract 2
- 229960004295 valine Drugs 0.000 abstract 2
- 239000004474 valine Chemical group 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Chemical group 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 abstract 1
- 229940009098 aspartate Drugs 0.000 abstract 1
- 229960003646 lysine Drugs 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 229960001153 serine Drugs 0.000 abstract 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
- 229960002898 threonine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente descripción se refiere a polipéptidos diseñados por ingeniería que comprenden dominios de degradación, compuestos, composiciones y métodos para su preparación y uso en la degradación de proteínas diseñadas por ingeniería en células. Reivindicación 1: Un polipéptido diseñado por ingeniería que comprende un dominio de degradación, en donde el dominio de degradación comprende la secuencia de aminoácidos FCX¹X²CGX³X⁴ (SEC ID Nº 1), en donde: X¹ se selecciona de asparagina, aspartato, glicina, glutamina, metionina, histidina, triptófano, isoleucina, arginina, leucina, valina, treonina y fenilalanina, X² se selecciona de glutamina, arginina, histidina, leucina, fenilalanina, tirosina, triptófano, isoleucina, valina y metionina, X³ se selecciona de alanina, serina, cisteína, arginina, leucina, isoleucina, metionina y glicina, y X⁴ se selecciona de serina, metionina, lisina, isoleucina, valina, histidina, glutamina, arginina, fenilalanina y triptófano. Reivindicación 72: Un método para reducir el nivel del polipéptido diseñado por ingeniería de acuerdo con cualquiera de las reivindicaciones 1 a 61, que comprende poner en contacto el polipéptido diseñado por ingeniería con un agente de degradación seleccionado de: los compuestos del grupo de fórmula (1), y tautómeros de los mismos, y sales farmacéuticamente aceptables de los mismos, y sales farmacéuticamente aceptables de tautómeros de los mismos. Reivindicación 73: Un método para reducir el nivel de un polipéptido diseñado por ingeniería en una célula, que comprende poner en contacto la célula de acuerdo con cualquiera de las reivindicaciones 64 a 70 con un agente de degradación seleccionado de: los compuestos del grupo de fórmula (1), y tautómeros de los mismos, y sales farmacéuticamente aceptables de los mismos, y sales farmacéuticamente aceptables de tautómeros de los mismos. Reivindicación 94: El método de cualquiera de las reivindicaciones 91 a 93, en donde el agente de degradación es un compuesto seleccionado a partir de: los compuestos del grupo de fórmula (1), y tautómeros de los mismos, sales farmacéuticamente aceptables de los mismos y sales farmacéuticamente aceptables de tautómeros de los mismos. Reivindicación 95: Un compuesto seleccionado a partir de: los compuestos del grupo de fórmula (1), y tautómeros de los mismos, sales farmacéuticamente aceptables de los mismos y sales farmacéuticamente aceptables de tautómeros de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163230225P | 2021-08-06 | 2021-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126718A1 true AR126718A1 (es) | 2023-11-08 |
Family
ID=83692652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102109A AR126718A1 (es) | 2021-08-06 | 2022-08-05 | Composiciones y métodos para la degradación selectiva de proteínas diseñadas por ingeniería |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230095912A1 (es) |
| EP (1) | EP4380582A1 (es) |
| JP (1) | JP2024528988A (es) |
| KR (1) | KR20240043780A (es) |
| CN (1) | CN117794554A (es) |
| AR (1) | AR126718A1 (es) |
| AU (1) | AU2022324621A1 (es) |
| CA (1) | CA3223636A1 (es) |
| CL (1) | CL2024000305A1 (es) |
| CO (1) | CO2024001133A2 (es) |
| IL (1) | IL309653A (es) |
| MX (1) | MX2024000901A (es) |
| TW (1) | TW202321278A (es) |
| WO (1) | WO2023015283A1 (es) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994A (en) | 1849-01-02 | Combined beading-tool and circular shears | ||
| US136A (en) | 1837-03-03 | Mode of molding candles | ||
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| CA2370103C (en) | 1999-04-29 | 2011-08-02 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| CN1352301A (zh) * | 2000-11-02 | 2002-06-05 | 上海博德基因开发有限公司 | 一种新的多肽——人二氢乳清酸酶9.46和编码这种多肽的多核苷酸 |
| TWI830576B (zh) | 2017-07-10 | 2024-01-21 | 美商西建公司 | 抗增生化合物及其使用方法 |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| TWI829655B (zh) * | 2017-10-18 | 2024-01-21 | 瑞士商諾華公司 | 用於選擇性蛋白質降解的組合物及方法 |
| US12049482B2 (en) * | 2017-10-31 | 2024-07-30 | The Brigham And Women's Hospital, Inc. | Molecular switch-mediated control of engineered cells |
| US20220251152A1 (en) * | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
| CN110438112B (zh) * | 2019-08-16 | 2021-09-10 | 苏州科宁多元醇有限公司 | 一种d-阿洛酮糖-3-差向异构酶的突变体及其应用 |
-
2022
- 2022-08-05 IL IL309653A patent/IL309653A/en unknown
- 2022-08-05 AR ARP220102109A patent/AR126718A1/es unknown
- 2022-08-05 AU AU2022324621A patent/AU2022324621A1/en active Pending
- 2022-08-05 US US17/817,777 patent/US20230095912A1/en active Pending
- 2022-08-05 MX MX2024000901A patent/MX2024000901A/es unknown
- 2022-08-05 TW TW111129489A patent/TW202321278A/zh unknown
- 2022-08-05 WO PCT/US2022/074589 patent/WO2023015283A1/en active Application Filing
- 2022-08-05 CA CA3223636A patent/CA3223636A1/en active Pending
- 2022-08-05 JP JP2024506674A patent/JP2024528988A/ja active Pending
- 2022-08-05 CN CN202280054544.9A patent/CN117794554A/zh active Pending
- 2022-08-05 EP EP22790152.7A patent/EP4380582A1/en active Pending
- 2022-08-05 KR KR1020247007065A patent/KR20240043780A/ko unknown
-
2024
- 2024-01-31 CL CL2024000305A patent/CL2024000305A1/es unknown
- 2024-02-01 CO CONC2024/0001133A patent/CO2024001133A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117794554A (zh) | 2024-03-29 |
| EP4380582A1 (en) | 2024-06-12 |
| CA3223636A1 (en) | 2023-02-09 |
| KR20240043780A (ko) | 2024-04-03 |
| CO2024001133A2 (es) | 2024-03-07 |
| JP2024528988A (ja) | 2024-08-01 |
| CL2024000305A1 (es) | 2024-06-14 |
| AU2022324621A1 (en) | 2024-01-18 |
| US20230095912A1 (en) | 2023-03-30 |
| TW202321278A (zh) | 2023-06-01 |
| WO2023015283A1 (en) | 2023-02-09 |
| IL309653A (en) | 2024-02-01 |
| MX2024000901A (es) | 2024-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014120804A (ru) | Моноклональные антитела и способы их применения | |
| CA2614006C (en) | Stable aqueous systems comprising proteins | |
| ES2585580T3 (es) | Péptidos novedosos antienvejecimiento y composición cosmética y/o farmacéutica que los contiene | |
| RU2012151500A (ru) | Композиции и способы, пригодные для снижения вязкости белковосодержащих составов | |
| JP2013520426A5 (es) | ||
| AR126718A1 (es) | Composiciones y métodos para la degradación selectiva de proteínas diseñadas por ingeniería | |
| AR043234A1 (es) | Metodo para reducir la formacion de acrilamida en alimentos | |
| RU2014133818A (ru) | Стабилизированный состав pth | |
| NZ597001A (en) | Methods and compositions for improving sugar transport, mixed sugar fermentation, and production of biofuels | |
| RU2013103093A (ru) | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкаганов | |
| DK0623606T3 (da) | Peptidketoner som interleukin-1beta-omdannende enzyminhibitorer | |
| PE20081655A1 (es) | Medios racionalmente disenados para cultivo celular | |
| CA2797140A1 (en) | Improved cell culture medium | |
| MX2022002850A (es) | Formulaciones de anticuerpos anti-il-23p19. | |
| Leon et al. | Effects of glucocorticois administration on the incorporation of labelled amino acids into protein by cell-free rat-liver systems | |
| Dobashi et al. | Inhibition of steroidogenesis in Leydig cells by exogenous nitric oxide occurs independently of steroidogenic acute regulatory protein (star) mRNA | |
| de la Llosa et al. | On the mechanism of reversible inactivation of luteinizing hormone by urea | |
| ES2607490T3 (es) | Péptidos antienvejecimiento activadores del proteasoma y composiciones que los contienen | |
| AU2002309121A1 (en) | Amino-acid-based compositions, suitable in therapy for the healing and/or mending of wounds and lesions, in particular for application in the ophthalmic field | |
| Caro et al. | A combination of intracellular leucine with either glutamate or aspartate inhibits autophagic proteolysis in isolated rat hepatocytes | |
| Moat et al. | The amino acid nutrition of yeast in relationship to biotin deficiency | |
| CN104674332B (zh) | 镁合金支架的处理液及处理方法 | |
| JPWO2020009215A5 (es) | ||
| MX2020011842A (es) | Metodo para reparar cabello que ha sido sometido a tratamientos oxidantes. | |
| CN105345053A (zh) | 一种夹持内径用浮动卡爪 |